Navigation Links
Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics
Date:10/29/2008

lead attorney and partner at Hagens Berman Sobol Shapiro. "Spectranetics, like many companies, fell prey to a bad market and unfortunately decided to mislead investors to try and turn things around."

The lawsuit seeks to represent anyone who purchased or acquired company stock between April 19, 2007 and Sept. 4, 2008.

The lawsuit alleges company executives issued false and misleading statements concerning operations and finances, which caused company stock to trade at an artificially inflated price. Defendants knowingly shared misinformation and failed to communicate accurate reports, the complaint states.

The shock came to investors on Sept. 4, 2008 when reports surfaced that federal officials raided the company. Almost immediately, NASDAQ halted trading of Spectranetics stock.

According to court documents, Spectranetics issued a press release revealing more information about the search warrants, disclosing the company was jointly served by the FDA and U.S. Immigration and Customs Enforcement regarding the promotion, use, testing, marketing and sales of certain Spectranetics products. The warrants also addressed payments made to medical personnel.

The suit claims the effect on company stock was significant as it fell 47 percent to $4.73 per share. Today the company stock stands at $2.74, after trading at a high of $16.00 per share in December 2007.

The allegations against Spectranetics include: failing to notify investors and the public that the company lacked effective regulatory compliance controls; illegally and extensively marketing its laser and catheters for uses not approved by the FDA; failing to report to the FDA that tests found its laser caused significant damage to stents when used in clinical trials; illegally testing several products without FDA approval; the company's lack of effective internal controls and the material inflation of the company's financial results.

The complaint alleges the defendants,
'/>"/>

SOURCE Hagens Berman Sobol Shapiro
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation
2. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
3. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
4. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
5. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
6. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
7. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
8. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
9. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
10. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
11. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6QLT Announces Second Quarter Results for 2009 52895 1QLT Announces Second Quarter Results for 2009 52895 2QLT Announces Second Quarter Results for 2009 52895 3QLT Announces Second Quarter Results for 2009 52895 4QLT Announces Second Quarter Results for 2009 52895 5QLT Announces Second Quarter Results for 2009 52895 6QLT Announces Second Quarter Results for 2009 52895 7QLT Announces Second Quarter Results for 2009 52895 8QLT Announces Second Quarter Results for 2009 52895 9QLT Announces Second Quarter Results for 2009 52895 10QLT Announces Second Quarter Results for 2009 52895 11QLT Announces Second Quarter Results for 2009 52895 12QLT Announces Second Quarter Results for 2009 52895 13QLT Announces Second Quarter Results for 2009 52895 14QLT Announces Second Quarter Results for 2009 52895 15QLT Announces Second Quarter Results for 2009 52895 16QLT Announces Second Quarter Results for 2009 52895 17NeoGenomics Reports Second Quarter 2009 Results 13224 1NeoGenomics Reports Second Quarter 2009 Results 13224 2NeoGenomics Reports Second Quarter 2009 Results 13224 3NeoGenomics Reports Second Quarter 2009 Results 13224 4NeoGenomics Reports Second Quarter 2009 Results 13224 5NeoGenomics Reports Second Quarter 2009 Results 13224 6NeoGenomics Reports Second Quarter 2009 Results 13224 7NeoGenomics Reports Second Quarter 2009 Results 13224 8NeoGenomics Reports Second Quarter 2009 Results 13224 9GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite 52890 1GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite 52890 2